Invitrogen™ FLT3 Ligand; Recombinant Human Protein 

Description

The FLT3 Ligand CTS™ Recombinant Human is expressed in HEK-293 cells and verified for activity through dose-dependent proliferation of human OCI-AML5 cells.

• Qualified—helps reduce your burden in qualifying reagents for regulatory submission in cell therapy applications
• Highly Pure—minimizes interference from other proteins or contaminants
• Active—get more results with less protein

Simplified Transition into Clinical Research

GIBCO™ Cell Therapy Systems (CTS™) products are of high quality and supplied with harmonized documentation such as Certificates of Analysis, Certificates of Origin, and access to authorization letters for our Drug Master Files, as appropriate. The GIBCO™ CTS™ product line enables you to reduce your burden in qualifying reagents during your transition from research applications to clinical applications.

High Purity

To help verify that GIBCO™ CTS™ Recombinant growth factors are of the highest quality, each protein is analyzed for purity, along with structural homogeneity, to help ensure a biologically active protein. The purity of each GIBCO™ CTS™ recombinant growth factor is verified by SDS-PAGE to be over 95% pure and to have endotoxin levels below 0.1ng/μg.

High Biological Activity

All GIBCO™ CTS™ Recombinant growth factors are verified for activity. Each lot has its own ED50 determined using an activity assay based on a specific function of the growth factor. The activity of our FLT3 Ligand CTS™ Recombinant Human growth factor is determined by the dose-dependent proliferation of human OCI-AML5 cells to have an ED50 range from 0.5–1.0ng/mL (specific activity: 2.0 × 10⁶–1.0 × 10⁶ units/mg). Optimal concentration for individual applications should be determined by a dose response assay.